Abstract
CAN is a high-affinity anti-IL–1β antibody that was superior to placebo (PBO) at preventing cardiac adverse events (AEs) in the CANTOS study. In an exploratory analysis of CANTOS, CAN was associated with significant reductions in NSCLC incidence and mortality, suggesting that CAN inhibition of the IL-1β pathway may have reduced the rate of progression, invasiveness, and metastatic spread of lung cancers undiagnosed at trial entry. Here, we show efficacy and safety of CAN as adjuvant therapy vs PBO in pts with completely resected NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
